Embryo freezing is now routine in IVF — but routine does not mean simple. Every embryo stored in liquid nitrogen at –196°C represents a complex medical process: ovarian stimulation, follicle retrieval, fertilization, embryo culture. Technical failures during freezing cannot be undone. They cost time, money, and significant emotional burden for patients.
This guide explains how embryo cryopreservation works technically, which developmental stages matter most, and what IVF laboratories need to operate safely and reproducibly.
In IVF, not every embryo from a stimulation cycle is used for immediate transfer. Good-quality supernumerary embryos are cryopreserved — for later cycles, for siblings, or as a safety net if the first transfer fails.
Embryos are typically frozen at two developmental stages:
The clinical trend is clearly toward blastocyst culture and blastocyst freezing. Better selection quality — not every embryo reaches the blastocyst stage — combined with improved outcomes makes this the current preference at most experienced IVF centers.
Vitrification has almost entirely replaced slow cooling for embryo cryopreservation. Ultra-rapid cooling (exceeding 1,000°C per minute) prevents intracellular ice crystal formation — the primary mechanism of cryopreservation damage.
Modern vitrification media (cryoprotective agents including ethylene glycol and DMSO) combined with specialized carrier systems (CryoTops, cryostraws) achieve post-thaw survival rates above 90% for blastocysts in experienced embryology teams.
Importantly: vitrification does not require a separate controlled rate freezer. The ultra-rapid cooling occurs through direct immersion in liquid nitrogen. What clinics need is a reliable LN₂ storage infrastructure.
Not every embryo protocol relies exclusively on vitrification. For specific research applications, cleavage-stage embryos in certain protocols, and laboratories that maintain slow cooling for clinical reasons, the controlled rate freezer remains an essential instrument.
The BIOFREEZE® from Consarctic® controls the cooling rate with precision. Its TC-Aktiv function automatically detects latent heat (crystallization heat) released within the sample and triggers a compensatory cooling impulse — minimizing ice crystal formation and maximizing post-thaw survival rates even in slow cooling protocols.
After freezing — whether by vitrification or slow cooling — embryos must be stored at –196°C. For reproductive medicine applications, Consarctic® recommends exclusively:
Both series are validated for IVF and reproductive medicine. Both use the eccentric neck opening that reduces LN₂ consumption by up to 30%.
Note: For embryo storage, use only ABV+ and ABS+ Series tanks. BSD+ and BSF+ Series are not designated for reproductive medicine applications.
Human embryo cryopreservation operates under strict regulatory requirements. In Europe, EU Tissue Directive 2004/23/EC defines the framework for licensing, operation, and quality assurance of tissue establishments — a category that includes IVF laboratories.
Practical requirements include:
Consarctic® delivers all systems with complete IQ/OQ documentation. Institutions including Charité Universitätsmedizin Berlin and Tirol Kliniken rely on this qualification documentation for their regulatory compliance.
Poorly frozen embryos are either non-viable after thawing or show structural damage that reduces implantation probability. The clinical cost is twofold: the embryo itself is lost — and the patient faces another complete stimulation and retrieval cycle.
The emotional and financial burden of one IVF cycle is significant. Technical failures in cryopreservation are not acceptable risks in this context.
Cryopreserved embryos can be stored at –196°C indefinitely from a biological standpoint. Legal frameworks in individual countries may limit permitted storage duration or define specific intended uses, but biological studies show no significant quality decline over more than 10 years of properly managed storage.
A blastocyst is an embryo at the blastocyst stage — typically Day 5 or 6 after fertilization. It consists of approximately 100–200 cells and shows clear differentiation into an inner cell mass (which becomes the fetus) and a trophoblast (which becomes the placenta). Blastocysts show higher implantation rates than cleavage-stage embryos.
In a fresh transfer, the embryo is transferred in the same stimulation cycle. In a frozen embryo transfer (FET), a previously cryopreserved embryo is transferred in a later cycle, often with hormonal preparation. Studies show FET often achieves comparable or better implantation rates than fresh transfers, partly because the uterine environment is more favorable in a non-stimulated cycle.
For vitrification: vitrification media, carrier systems (CryoTops), ABV+ or ABS+ Series cryogenic tanks, LN₂ supply, and a monitoring system. For slow cooling protocols, add: BIOFREEZE® Controlled Rate Freezer. For all applications: IQ/OQ documentation and qualified embryology staff.
Embryo cryopreservation is not a side activity of the IVF laboratory. It is a distinct clinical discipline requiring its own infrastructure, protocols, and qualification.
Consarctic GmbH supports IVF laboratories in planning, equipping, and commissioning their cryopreservation infrastructure. With more than 20 years serving leading reproductive medicine centers worldwide, contact us to discuss your laboratory requirements.